| Name | Title | Contact Details |
|---|---|---|
Tracy Vardeman |
Vice President of Strategic Planning/Marketing | Profile |
Janice Howser |
Director - Compensation and Hris | Profile |
Diane Poirot |
SVP/Chief Human Resources Officer | Profile |
Heartland Regional Medical Center is offering patients and physicians in southern Illinois access to the latest diagnositc imaging technology. Our 64 Slice CT (computed tomography) scanner produces crisp, detailed images of the body in just seconds. Our
LHM Physical Therapy Institute is a full-service outpatient physical therapy provider in Pennsylvania that offers personalized care to enhance patients quality of life.
Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. At Evolus, you have the opportunity to be part of a movement. A performance beauty company changing the game. We are bringing innovation and forward-thinking technology to an industry desperately wanting frictionless experiences. Our work disrupts the status quo, but most importantly, we will make an impact, we are customer-centric - always. Because of this, we are excited to step through the door each morning. We help each other climb; we don`t climb over one another. We believe that integrity and a team-driven environment connect entrepreneurial minds. Getting goose bumps? Good. Join the Evolus movement, and let`s see where you can put your talents to work.
Ability Services Network Inc is a Duluth, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.